PhaseBio Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0324
- Today's High:
- $0.04
- Open Price:
- $0.04
- 52W Low:
- $0.0111
- 52W High:
- $1.19
- Prev. Close:
- $0.038
- Volume:
- 285749
Company Statistics
- Market Cap.:
- $3.50 million
- Book Value:
- -2.355
- Revenue TTM:
- $818000
- Operating Margin TTM:
- -12738.63%
- Gross Profit TTM:
- $-91276000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -106.07%
- Return on Equity TTM:
- -3091.02%
Company Profile
PhaseBio Pharmaceuticals Inc had its IPO on 2018-10-18 under the ticker symbol PHAS.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. PhaseBio Pharmaceuticals Inc has a staff strength of 60 employees.
Stock update
Shares of PhaseBio Pharmaceuticals Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.03 - $0.04, and closed at $0.04.
This is a +5.26% increase from the previous day's closing price.
A total volume of 285,749 shares were traded at the close of the day’s session.
In the last one week, shares of PhaseBio Pharmaceuticals Inc have increased by +75.44%.
PhaseBio Pharmaceuticals Inc's Key Ratios
PhaseBio Pharmaceuticals Inc has a market cap of $3.50 million, indicating a price to book ratio of 26.18 and a price to sales ratio of 4.2727.
In the last 12-months PhaseBio Pharmaceuticals Inc’s revenue was $818000 with a gross profit of $-91276000 and an EBITDA of $-102262000. The EBITDA ratio measures PhaseBio Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PhaseBio Pharmaceuticals Inc’s operating margin was -12738.63% while its return on assets stood at -106.07% with a return of equity of -3091.02%.
In Q2, PhaseBio Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98%.
PhaseBio Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PhaseBio Pharmaceuticals Inc’s profitability.
PhaseBio Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.1964 and a EV to EBITDA ratio of -0.0016. Its price to sales ratio in the trailing 12-months stood at 4.2727.
PhaseBio Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.17 million
- Total Liabilities
- $24.68 million
- Operating Cash Flow
- $-58000.00
- Capital Expenditure
- $58000
- Dividend Payout Ratio
- 0%
PhaseBio Pharmaceuticals Inc ended 2024 with $22.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.17 million while shareholder equity stood at $-117398000.00.
PhaseBio Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $24.68 million in other current liabilities, 50000.00 in common stock, $-419600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.80 million and cash and short-term investments were $7.80 million. The company’s total short-term debt was $4,503,000 while long-term debt stood at $0.
PhaseBio Pharmaceuticals Inc’s total current assets stands at $11.56 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $6.32 million and inventory worth $0.
In 2024, PhaseBio Pharmaceuticals Inc's operating cash flow was $-58000.00 while its capital expenditure stood at $58000.
Comparatively, PhaseBio Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.04
- 52-Week High
- $1.19
- 52-Week Low
- $0.0111
- Analyst Target Price
- $16
PhaseBio Pharmaceuticals Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $1.19 and a 52-week low of $1.19. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $0.06 and 200-day moving average was $0.71 The short ratio stood at 1.89 indicating a short percent outstanding of 0%.
Around 672.1% of the company’s stock are held by insiders while 5520.5% are held by institutions.
Frequently Asked Questions About PhaseBio Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.